SEC Form SC 13G/A filed by West Pharmaceutical Services Inc. (Amendment)

2/14/23 12:37:59 PM ET

Medical/Dental Instruments

Health Care

Get the next $WST alert in real time by email

SC 13G/A 1 wst13gadec22.txt UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 8) WEST PHARMACEUTICAL SERVICES (Name of Issuer) COMMON STOCK (Title of Class of Securities) 955306105 (CUSIP NUMBER) December 31, 2022 (Date of Event which Requires Filing of Statement) Check the appropriate box to designate the Rule pursuant to which this Schedule is filed: [x] Rule 13d - 1(b) Rule 13d - 1(c) Rule 13d - 1(d) 1. Name of Reporting Person T. ROWE PRICE ASSOCIATES, INC. 52-0556948 2. Check the Appropriate Box if a Member of a Group NOT APPLICABLE 3. SEC Use Only 4. Citizenship or Place of Organization Maryland Number of Shares Beneficially Owned by Each Reporting Person With 5. Sole Voting Power* 547,161 6. Shared Voting Power* 0 7. Sole Dispositive Power* 2,301,161 8. Shared Dispositive Power 0 9. Aggregate Amount Beneficially Owned by Each Reporting Person 2,301,161 10. Check Box if the Aggregate Amount in Row (9) Excludes Certain Shares NOT APPLICABLE 11. Percent of Class Represented by Amount in Row 9 3.1% 12. Type of Reporting Person IA *Any shares reported in Items 5 and 6 are also reported in Item 7. Item 1(a) Name of Issuer: WEST PHARMACEUTICAL SERVICES Item 1(b) Address of Issuer's Principal Executive Offices: 530 HERMAN O. WEST DRIVE, EXTON, PENNSYLVANIA 19341 Item 2(a) Name of Person(s) Filing: (1) T. ROWE PRICE ASSOCIATES, INC. (Price Associates) Item 2(b) Address of Principal Business Office: 100 E. Pratt Street, Baltimore, MD 21202 Item 2(c) Citizenship or Place of Organization: (1) Maryland Item 2(d) Title of Class of Securities: COMMON STOCK Item 2(e) Cusip Number: 955306105 Item 3: The person filing this Schedule 13G is an: X Investment Adviser registered under Section 203 of the Investment Advisers Act of 1940 Item 4: Reference is made to Items 5-11 on the preceding pages of this Schedule 13G. Item 5: Ownership of Five Percent or Less of a Class This statement is being filed to report the fact that, as of the date of this report, the reporting person(s) has (have) ceased to be the beneficial owner of more than five percent of the class of securities. Item 6: Ownership of More than Five Percent on Behalf of Another Person (1) Price Associates does not serve as custodian of the assets of any of its clients; accordingly, in each instance only the client or the client's custodian or trustee bank has the right to receive dividends paid with respect to, and proceeds from the sale of, such securities. The ultimate power to direct the receipt of dividends paid with respect to, and the proceeds from the sale of, such securities, is vested in the individual and institutional clients which Price Associates serves as investment adviser. Any and all discretionary authority which has been delegated to Price Associates may be revoked in whole or in part at any time. Except as may be indicated if this is a joint filing with one of the registered investment companies sponsored by Price Associates which it also serves as investment adviser ("T. Rowe Price Funds"), not more than 5% of the class of such securities is owned by any one client subject to the investment advice of Price Associates. (2) With respect to securities owned by any one of the T. Rowe Price Funds, only the custodian for each of such Funds, has the right to receive dividends paid with respect to, and proceeds from the sale of, such securities. No other person is known to have such right, except that the shareholders of each such Fund participate proportionately in any dividends and distributions so paid. Item 7: Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company. Not Applicable Item 8: Identification and Classification of Members of the Group Not Applicable Item 9: Notice of Dissolution of Group Not Applicable Item 10: Certification By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect. T. Rowe Price Associates, Inc. hereby declares and affirms that the filing of Schedule 13G shall not be construed as an admission that Price Associates is the beneficial owner of the securities referred to, which beneficial ownership is expressly denied. Signature. After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct. T. ROWE PRICE ASSOCIATES, INC. Date: February 14, 2023 Signature: /s/ David Oestreicher Name & Title: David Oestreicher, Executive Vice President 12/31/2022

Get the next $WST alert in real time by email

Recent Analyst Ratings for

$WST

Date	Price Target	Rating	Analyst
12/2/2025	$285.00	Equal-Weight	Morgan Stanley
9/15/2025	$311.00	Buy	Rothschild & Co Redburn
6/24/2025	$245.00	Equal Weight	Barclays
3/18/2025	$275.00	Outperform	Evercore ISI
2/14/2025	$250.00	Hold → Buy	Deutsche Bank
1/8/2025	$400.00	Buy	Citigroup
12/13/2024		Peer Perform	Wolfe Research
12/12/2024	$350.00 → $390.00	Neutral → Buy	UBS

More analyst ratings

SEC Form SC 13G/A filed by West Pharmaceutical Services Inc. (Amendment)

2/14/23 12:37:59 PM ET

$WST

Medical/Dental Instruments

Health Care

Get the next $WST alert in real time by email

Recent Analyst Ratings for

$WST

Date	Price Target	Rating	Analyst
12/2/2025	$285.00	Equal-Weight	Morgan Stanley
9/15/2025	$311.00	Buy	Rothschild & Co Redburn
6/24/2025	$245.00	Equal Weight	Barclays
3/18/2025	$275.00	Outperform	Evercore ISI
2/14/2025	$250.00	Hold → Buy	Deutsche Bank
1/8/2025	$400.00	Buy	Citigroup
12/13/2024		Peer Perform	Wolfe Research
12/12/2024	$350.00 → $390.00	Neutral → Buy	UBS

More analyst ratings

SEC Form SC 13G/A filed by West Pharmaceutical Services Inc. (Amendment)

Crush Q1 2026 with the Best AI Superconnector

Recent Analyst Ratings for
$WST

SEC Form SC 13G/A filed by West Pharmaceutical Services Inc. (Amendment)

Crush Q1 2026 with the Best AI Superconnector

Recent Analyst Ratings for
$WST

$WST
Analyst Ratings

Morgan Stanley initiated coverage on West Pharm with a new price target

Rothschild & Co Redburn initiated coverage on West Pharm with a new price target

Barclays initiated coverage on West Pharm with a new price target

$WST
SEC Filings

Amendment: SEC Form SCHEDULE 13G/A filed by West Pharmaceutical Services Inc.

SEC Form 10-Q filed by West Pharmaceutical Services Inc.

West Pharmaceutical Services Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits

$WST
Press Releases

West Signs Agreement to Sell the Manufacturing and Supply Rights for SmartDose® 3.5mL On-Body Delivery System to AbbVie

AbbVie to Acquire Arizona Manufacturing Facility, Further Strengthening Manufacturing Capabilities in the United States

West to Participate in Upcoming Investor Conference

$WST
Insider Trading

SEC Form 4 filed by Director Haugen Janet Brutschea

SEC Form 4 filed by SVP, GC & Corporate Secretary Finch Norman D. Jr.

SEC Form 3 filed by new insider Finch Norman D. Jr.

$WST
Financials

West Declares Quarterly Dividend

West Reports Third-Quarter 2025 Results

West to Host Third-Quarter 2025 Conference Call

$WST
Leadership Updates

West Welcomes Robert McMahon as Incoming Chief Financial Officer

Sotera Health Appoints Karen Flynn to Board of Directors

West Announces Executive Leadership Appointments

$WST
Large Ownership Changes